Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sgi-1776. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 known ✓ | P11309 | 19/20 | 1.00 |
| ▸ | PIM3 known ✓ | Q86V86 | 2/20 | 1.00 |
| ▸ | PIM2 known ✓ | Q9P1W9 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 1/20 | 1.00 |
| ▸ | PKN1 | Q16512 | 1/20 | 1.00 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 1.00 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 1/20 | 1.00 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 1.00 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 1.00 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sgi-1776 SCHEMBL102498 | 1.00 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| Sgi-1776 SCHEMBL19923098 | 0.96 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| Sgi-1776 SCHEMBL29401822 | 0.96 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL140271 | 0.93 | PIM1 (0.89) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL103050 | 0.91 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102377 | 0.91 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102154 | 0.91 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102700 | 0.89 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL102535 | 0.89 | PIM1 (1.00) | PIM1KCNH2FLT3PIM3PIM2 | |
| SCHEMBL22421445 | 0.89 | PIM1 (0.80) | PIM1KCNH2FLT3PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025125504-A1 | COMBINED AGENTS WITH SYNERGISTIC EFFECTS AGAINST GLIOMAS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2025-06-19 | — | — | WO | disclosed |
| EP-4570246-A1 | COMBINED AGENTS WITH SYNERGISTIC EFFECTS AGAINST GLIOMAS | Eberhard Karls Universität Tübingen Medizinische Fakultät (DE) | 2025-06-18 | — | — | EP | disclosed |
| US-12324817-B2 | Method of inducing dedifferentiation of somatic cells with small molecules to prepare rejuvenated mesenchymal stem cells and uses thereof | Shenzhen Alpha Biopharmaceutical Co. Ltd. (CN) | 2025-06-10 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| EP-4520828-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | The Schepens Eye Research Institute, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| US-20250011881-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-20230398130-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-14 | — | — | US | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| US-20230265432-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | Sanford Burnham Prebys Medical Discovery Institute | 2023-08-24 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-20230053688-A1 | METHODS TO ALTER LATENCY IN EBV+ MALIGNANCIES | CORNELL UNIVERSITY | 2023-02-23 | — | — | US | disclosed |
| US-20220323406-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-10-13 | — | — | US | disclosed |
| WO-2022166860-A1 | PIM KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2022-06-16 | — | — | US | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229662-B2 | Compositions and methods for the treatment of aberrant angiogenesis | VEGFA, PGF, FLT4 | PIM1 3266/4885PIM3 3431/4885PIM2 3600/4885 |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | PIM1 3620/4885PIM3 2213/4885PIM2 3907/4885 |
| US-20220184109-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS | VEGFA, PGF, FLT4 | PIM1 3266/4885PIM3 3431/4885PIM2 3600/4885 |
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | PIM1 1090/4885PIM3 1252/4885PIM2 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.